GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medexus Pharmaceuticals Inc (TSX:MDP) » Definitions » Retained Earnings

Medexus Pharmaceuticals (TSX:MDP) Retained Earnings : C$-87.5 Mil (As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Medexus Pharmaceuticals Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Medexus Pharmaceuticals's retained earnings for the quarter that ended in Dec. 2024 was C$-87.5 Mil.

Medexus Pharmaceuticals's quarterly retained earnings increased from Jun. 2024 (C$-85.4 Mil) to Sep. 2024 (C$-84.2 Mil) but then declined from Sep. 2024 (C$-84.2 Mil) to Dec. 2024 (C$-87.5 Mil).

Medexus Pharmaceuticals's annual retained earnings declined from Mar. 2022 (C$-82.6 Mil) to Mar. 2023 (C$-87.6 Mil) but then increased from Mar. 2023 (C$-87.6 Mil) to Mar. 2024 (C$-87.0 Mil).


Medexus Pharmaceuticals Retained Earnings Historical Data

The historical data trend for Medexus Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medexus Pharmaceuticals Retained Earnings Chart

Medexus Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -47.61 -78.39 -82.61 -87.61 -86.96

Medexus Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -87.21 -86.96 -85.36 -84.22 -87.54

Medexus Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Medexus Pharmaceuticals  (TSX:MDP) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Medexus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.
Executives
Brendon Buschman Senior Officer
Mike Mueller Director
Benoit Gravel Director
Stephen William Nelson Director
Kenneth D'entremont Director, Senior Officer
Marcel Pascal Konrad Senior Officer
Brian Peters Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Roland Boivin Senior Officer
Michael Pine Senior Officer
Glenn Tate Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Richard Labelle Senior Officer
Benoît Hébert Senior Officer